Even though less than 1% of uveal melanoma patients are found to have radiographic or clinical evidence of distant disease at the time of treatment for their intraocular disease, they carry a lifetime risk of disease recurrence, with approximately 50% of patients ultimately developing fatal metastases. Despite this significant risk, there is no consensus within the ophthalmologic or oncologic community regarding the role of surveillance for detection of metastatic disease in these patients. The lack of consensus is due to the notable absence of clear data regarding the best radiologic or serum surveillance modalities, the optimal frequency of testing, or the ideal length of follow-up. Given the ability to assess prognosis by cytogenetics, gene expression profiling, or other methods, questions remain about whether surveillance strategies should be tailored by level of risk. Importantly, no survival benefit from the early detection of asymptomatic disease in uveal melanoma has been documented, resulting in controversy over the value of routine surveillance and advocacy from some clinicians to forego surveillance altogether. However, there are several factors supporting surveillance: the patient's enhanced emotional well-being, the potential to identify oligometastatic disease amenable to surgery or other local therapies, decreased morbidity/complications from advanced disease, and identification of patients eligible for clinical trials that assess novel therapies for advanced uveal melanoma. The selection of surveillance modality used varies according to local expertise and resources and may include serum markers (liver function tests and others) and/or imaging (chest x-ray, abdominal ultrasound, computed tomography, positron emission tomography, and magnetic resonance imaging). U veal melanoma is the most common primary intraocular malignancy, with an annual incidence of six per million adults in the United States. Despite successful treatment of the primary tumor, patients remain at risk for development of metastatic disease. In one of the largest multicenter randomized trials, the Collaborative Ocular Melanoma Study (COMS), 5-and 10-year cumulative metastasis rates were 25% and 34%, respectively, 1 and the median time from diagnosis of metastasis to death was six months. 2 In this study, less than 1% of patients had evidence of metastatic disease at the time of diagnosis of the primary lesion. 1 Uveal melanoma spreads predominantly via a hematogenous route, with the liver the most common site of both initial metastases detected and involvement of metastases at death. Other sites can be affected. The sites of metastases at death in the COMS included liver in 91%, lung in 26%, bone in 18%, skin in 12%, and lymph nodes in 11% of patients. 2 There is signifıcant debate about the role of routine disease surveillance following defınitive management of uveal melanoma, which may be reflective of the differing patient populations and practice patterns between ophthalmology and oncology. The risks of over-diagnosis and false-positive or false-negative results, as well as a poor cost-to-benefıt ratio, must be balanced against the potential benefıt that early diagnosis of recurrent disease could prevent premature death. Early detection of asymptomatic metastases may increase the ability to identify disease at a time when potentially curative treatments for oligometastatic disease could be attempted, reduce the risk of developing signifıcant tumor-related morbidity, and identify patients who may be eligible for participation on a clinical trial assessing novel agents for the treatment of uveal melanoma. Indeed, recent advancements in understanding the underlying biology of uveal melanoma and the development of novel targeted agents offer new optimism in what was once a dismal landscape. Finally, even if the effect of surveillance on survival is minimal, surveillance may provide the patient and family with other valuable advantages, including an improved emotional well-being and an opportunity to make future plans.
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Although no prospective randomized trials of routine surveillance have been conducted in uveal melanoma, they have been conducted in patients with resected colorectal cancer. Individual randomized trials in patients with colorectal cancer did not demonstrate a survival benefıt from surveillance, but three meta-analyses did suggest a modest and signifıcant survival benefıt. 3 Currently, the National Comprehensive Cancer Network (NCCN) recommends routine surveillance of colon cancer with clinical exam, serum marker, and computed tomography (CT) scans. In contrast, there are only scattered reports of surveillance in patients with uveal melanoma, with some suggesting a survival benefıt due to identifying patients eligible for resection or other locoregional treatment techniques for oligometastatic disease. [4] [5] [6] However, the effects of lead-time bias on these reports are unclear, and a literature review of 31 articles failed to demonstrate convincing evidence of a survival advantage from routine surveillance. 7, 8 These fındings have cast doubt over the utility of surveillance for metastatic uveal melanoma. Although various proposals have been suggested (at least for preoperative testing), 9 there is no current universally accepted screening approach. Questions remain regarding whether routine surveillance should be conducted, for whom surveillance should be performed, the frequency of testing, the duration of follow-up, and the optimal surveillance methodologies. Given the lack of consensus regarding routine surveillance in many cancers, it is important for patients to be educated regarding the pros and cons of surveillance, as well as the surveillance options that exist.
The discussion below examines the considerations surrounding routine surveillance for the development of metastatic disease following defınitive management of a primary uveal melanoma and outlines the various surveillance methodologies that are available (summarized in Table 1 ).
SERUM MARKERS Liver Function Tests
Given the overwhelming preponderance of hepatic involvement, the liver has become the primary focus of metastatic surveillance strategies.
This collection of serum liver function tests (LFTs) provides an indirect measure of hepatic function. It has the advantage of being relatively inexpensive and widely available. However, LFTs are limited by low sensitivity and a poor positive predictive value (PPV). 10 Elevations in LFTs are not specifıc to uveal melanoma but may be the result of inflammation, infection, other malignancies, or liver disease including alcohol and drugs. Groups have disagreed about the most sensitive component of the LFT panel, with some supporting lactate dehydrogenase and others favoring gamma-glutamyl transpeptidase and alkaline phosphatase. 11, 12 Nevertheless, Hicks and colleagues determined that no component had a sensitivity greater than 25%, and none had a positive predictive power greater than 50%. 12 This compares to troponin assays having a sensitivity of 98% and a PPV of approximately 96% in the diagnosis of myocardial infarction. 13 The COMS performed semiannual LFTs in conjunction with annual chest x-rays, and the determinations of sensitivity and specifıcity were consistent with earlier reports. The authors concluded that "better tests are needed to identify earlier metastatic disease." 2 A group from Canada agreed with the ineffectiveness of LFTs as a surveillance method, but it also highlighted a potential benefıt of its high negative predictive value. 10 By that group's calculation, it is important for patients to know "that they have a 97.5% chance or more of having no metastasis in the case of normal LFT results." 10 Of note, it has been suggested that LFTs in combination with other tests may be of value. Eskelin and colleagues from Finland predicted that semiannual LFTs in combination with an annual abdominal ultrasound will detect greater than 95% of asymptomatic patients. 11
Other Serum Markers
Other serum markers have been assessed as potential surveillance tools, including markers assessed in cutaneous melanoma (S-100ß); those elevated in other cancers (osteopontin, vascular endothelial growth factor, insulin-like growth factor 1, growth differentiation factor-15); and those found on histologic sections of metastatic uveal melanoma (melanoma inhibitory activity). [14] [15] [16] Despite predictions that combined multiple serum parameters may detect hepatic metastases at higher sensitivity than LFTs, these markers have not proven to be a robust predictor of metastatic disease nor have they been adopted into universal clinical practice. It is suggested that even although absolute serum levels are not useful, changes in levels over time may be. [14] [15] [16] Retrospective studies have demonstrated increasing levels of various markers in patients who have developed metastatic disease, but levels may also increase (to a different degree) in disease-free patients. Although they may increase in patients with recurrent disease, all of these values may remain within normal limits. 14, 15 No study has prospectively analyzed these as predictive markers for metastatic disease in a large cohort.
CIRCULATING TUMOR CELLS AND TUMOR DNA
As with other malignancies, there has been some interest in the detection of circulating uveal melanoma cells in peripheral
KEY POINTS
⅐ Approximately half of uveal melanoma patients develop metastases, which are ultimately fatal. ⅐ It is difficult to demonstrate that routine surveillance or earlier detection of metastatic disease improves patient survival. ⅐ Several factors support surveillance: the patient's enhanced emotional well-being, the potential to identify oligometastatic disease amenable to surgery or other local therapies, decreased morbidity/complications from advanced disease, and identification of patients eligible for clinical trials that assess novel therapies for advanced uveal melanoma. ⅐ Surveillance strategies vary and include monitoring serum markers such as liver function tests and radiographic imaging studies, including abdominal ultrasonography, CT, PET, and MRI. ⅐ Given the ability to assess prognosis by cytogenetics, gene expression profiling, or other methods, it may be sensible to stratify surveillance methods by risk of metastases.
blood. Detection methods have included immunohistochemistry, reverse transcriptase-polymerase chain reaction, an immunocytologic assay with tumor cell enrichment by immunomagnetic cell sorting and identifıcation of circulating tumor-derived DNA. 17, 18 The utility of identifying circulating tumor cells or DNA in the peripheral blood as a surveillance tool has demonstrated variable results and has not been widely employed. As methods of detection become more sophisticated and our understanding about circulating tumor cells deepens, this may become a more useful avenue for the detection of recurrent melanoma.
IMAGING Chest X-ray
Chest x-rays have the advantage of being noninvasive, inexpensive, and accessible. They were part of the COMS screening protocol and demonstrated a sensitivity of 32% when performed at baseline and annually 2 ; however, at the lower end of extremes, chest x-rays have demonstrated sensitivity as poor as 2%. 12 They have been criticized for having low yield, and they are no longer routinely recommended for use in surveillance because of the superiority of CT in detection of intrathoracic metastases.
Ultrasonography
Abdominal/liver ultrasonography is widely used for surveillance in Europe, but is less frequently used in the United States. 19 It is noninvasive, inexpensive, widely available, and, in the hands of an experienced operator, can have high sensitivity, even for smaller lesions. In Finland, semiannual ultrasounds in concert with LFT measurements are estimated to detect metastases in greater than 95% of asymptomatic patients. 11 A French study noted the ability of abdominal ultrasonography to detect hepatic disease even in patients with normal LFTs. 6 However, the technique relies on the operator and, in worse cases, has reported sensitivities as low as 14%. 12 Although false-negative rates have been reported as low as 3.4%, 10 the operator dependence of ultrasonography can result in false-negative rates as high as 20% to 25%. 20 Moreover, ultrasonographic evaluation can be limited by body habitus. For example, 1 cm of body fat results in attenuation of beam intensity by 50%. In the United States, where one-third of American adults are obese, ultrasonography may not be the imaging modality of choice.
Computed Tomography
CT has been used by some for routine radiographic surveillance in uveal melanoma, and it is used as a confırmatory study following an abnormal serum marker or abdominal ultrasound by others. It is less expensive, faster, and has greater availability in comparison to magnetic resonance imaging (MRI), and the whole-body can be imaged with relative ease. Compared with ultrasound, CT is operator-independent as patient images are generated by using a computed algorithm rather than via technician profıciency. There is no published study comparing CT and MRI for surveillance in uveal melanoma, and it is therefore diffıcult to make a useful comment on the appropriate choice between these approaches; however, there are reported cases in which only isolated foci of metastatic disease to the liver are imaged on CT, with more extensive disease identifıed by contemporaneous MRI. 21 A representative case is shown in Figure 1 . This may argue for greater sensitivity of MRI for extent of metastasis detection, but it does not necessarily translate into earlier detection of metastasis.
CT does have the disadvantage of possessing a very low positive predictive value. In a retrospective review at our center, 50 (55%) patients had abnormalities identifıed during their baseline surveillance CT of the abdomen, with only three ultimately diagnosed with confırmed metastases. This lack of specifıcity was present regardless of the institution where the scan was performed or whether a triphasic protocol CT scan was performed. 22 The high false-positive rate may result in further investigational procedures and potentially invasive diagnostic measures to explore what is ultimately benign disease. There has also been increased attention regarding the radiation exposure associated with CT scanning. Some predictions show that 2.0% of cancers in the United States will be attributable to CT scans. 23 In a recent report concentrating on CT surveillance in uveal melanoma patients, young women were determined to be most at risk from radiation exposure. 24 For example, for a 20-year-old woman receiving a semiannual positron emission tomography (PET)/CT over a 10-year period, "the lifetime attributable risk of cancer was estimated to be as high as 7.9%." 24 If included in a screening regimen, limiting the frequency and duration of CT scans should be considered in light of these possible radiation risks.
Positron Emission Tomography/Computed Tomography
PET/CT has also been used for surveillance of disease recurrence in patients with uveal melanoma. Practitioners may be attracted by the ease at which PET captures images of the entire body, as well as its utility for establishing whole-body staging. The literature has also applauded its ability to detect second cancers. 25 Some groups suggest this imaging format offers high sensitivity, calculated as 100% in one study, although this probably represents an overestimation because it was carried out only in patients suspected of having metastatic disease. 26 Although 100% of cutaneous melanomas are FDG positive, 41% of uveal melanomas may be FDG avid, 27 calling into question the utility of PET/CT in surveillance for recurrent uveal melanoma. 27 Coupled with the high expense of the test and the current image resolution, PET/CT has been deemed inferior to MRI at detecting small metastases. 28 PET imaging can identify recurrent uveal melanoma lesions greater than or equal to 1.2 cm; however, it has reportedly only detected 11% of lesions smaller than this size. 28 It may come as no surprise that PET often fails to detect the primary uveal malignancy owing to small size of the lesions and suboptimal CT beam collimation. Besides malignancy, inflammation and infection can be FDG avid. Thus there are concerns over both the high false-positive and false-negative results derived from PET images. In addition, even though the concomitant CT scan aids in localization of lesions, it also exposes the patient to radiation (see above). Therefore, PET/CT may be of limited value in the surveillance of uveal melanoma, with particular concerns of small metastases being overlooked.
Magnetic Resonance Imaging
MRI is a popular method for surveillance of uveal melanoma, particularly in high-risk patients. It is expensive and is limited by body habitus, the presence of metallic implants, and claustrophobia. It also restricts investigation to one region of the body rather than whole-body imaging. Similar to other techniques, MRI also has the drawback of false-positive fınd-ings: although it may be superior at identifying concerning lesions, it may not be adequate at distinguishing benign from malignant causes. 29 Like other imaging modalities, this may complicate the screening process with additional diagnostic assessments, taxing resources and placing patients at risk with invasive procedures. However, MRI does have advantages over other imaging devices. It provides high-resolution images, relative accessibility compared with PET/CT at some institutions, and functions without the use of radiation, making it a safe option for repeated testing, particularly for young women.
In other subspecialties of oncology, there is deliberation over which imaging modality is superior for detecting metastatic disease to the liver. In colorectal cancer, meta-analyses have been conducted to determine the optimal instrument. It was previously believed that, on a per-patient basis, PET was the most accurate test, and on a per-lesion basis, no difference could be found between a 1.5 tesla MRI and PET. However, an updated meta-analysis offers more data supporting the choice of MRI in the detection of colorectal metastases to the liver, particularly following administration of liverspecifıc contrast agents. 30 No meta-analysis of specifıc imaging modalities has been performed in uveal melanoma surveillance; however, the strength of MRI testing has been reported. The most convincing evidence in the literature comes from a group in England that prospectively evaluated the ability of MRI to detect asymptomatic liver metastases in high-risk uveal melanoma. 31 MRIs performed every six months were successful in detecting metastatic disease in 92% of patients before they had symptoms, and almost half the patients had fewer than fıve lesions measuring less than 2 cm in diameter. 31 
TAILORING OF SURVEILLANCE PLAN BY RISK OF RECURRENCE
There is a question as to whether surveillance of metastatic uveal melanoma should be stratifıed by risk of disease recurrence. Over the past decade, our ability to categorize uveal melanoma into low-and high-risk has increased thanks to contributions from genetic advancements. Molecular techniques for prognostication have become more sophisticated in recent years and include fluorescent in situ hybridization (FISH), multiplex ligation-dependent probe amplifıcation (MLPA), single nucleotide polymorphism (SNP) array, and gene expression profıling (GEP). An analysis that considers multiple variables such as clinical (age, presence of subretinal fluid or orange pigment, size of primary tumor, etc.); histologic (epitheloid cells, extrascleral invasion, intratumoral microvascular networks, higher mitotic activity, etc.); and genetic (chromosomal alterations, molecular pathway defects, GEP class or gene defects such as BAP1, etc.) risk factors can be used to determine a patient's risk for metastatic disease. 32 It may be sensible, therefore, to tailor surveillance measures to the patient's estimated risk of recurrence. For example, this may decrease the frequency and shorten the duration of testing for low-risk patients, while doing the opposite for those at high-risk (who may require, e.g., an MRI every 3 to 6 months for 5 to 10 years). Because some patients are prone to late metastases, one could argue that their screening should be prolonged.
Marshall and colleagues instituted a semiannual MRI screening program that targeted high-risk patients, defıned as predicted risk of metastatic death at fıve years greater than 50%, and detected asymptomatic disease in 83/90 (92%) of patients. Stratifying surveillance strategies by risk may make better use of resources and be both time and cost effective. However, the benefıt of prolonged and more frequent surveillance must be weighed against the risks associated with extended imaging.
CONCLUSION
There is an absence of clear data regarding appropriate radiographic surveillance for patients with uveal melanoma following treatment of the primary lesion. Opinions vary regarding the utility of routine surveillance, the ideal patient in need of aggressive surveillance, the optimal blood tests and imaging modalities for use in surveillance, the appropriate interval between testing, and the ideal duration of follow-up.
The optimal imaging modality or modalities used for routine surveillance can vary depending on local resources and expertise. MRI appears superior to other imaging modalities at detecting small liver metastases, particularly those measuring less than 1 cm in diameter, but is not necessarily superior at detecting metastasis at an earlier rate that impacts survival. CT imaging of the total body with triphasic liver images may be equally as sensitive at detecting early metastasis; however, this must be balanced with the frequency and duration of radiation exposure. Ultrasonography is often used in Europe and, depending on the operator and the characteristics of the patient, can also be sensitive for the detection of small liver lesions. PET/CT appears less sensitive than traditional CT or MRI for detection of small disease in the liver and may have a higher false-positive rate.
Given the limited data available, the decision to pursue a structured surveillance should be made after a detailed discussion regarding the risks, benefıts, and limitations of available tests is conducted between the patient and physician performing the surveillance. If surveillance is elected, the interval could be tailored to the estimated risk of recurrence, with consideration for a more intensive surveillance schedule for those at higher risk of recurrence. For these patients, it may be reasonable to perform routine imaging on an every 3-to 6-month interval. For those at lower risk, imaging at an every 6-to 12-month interval may be appropriate. The optimal duration of follow-up remains controversial. Although late recurrences (more than 10 years after the initial diagnosis of disease) are well documented in uveal melanoma, the benefıt of routine radiographic follow-up beyond 10 years must be weighed against the risks and costs associated with continued imaging.
